Skip to content
Open access

Imaging the therapeutic effects of cerebral endothelial cell derived exosome treatment of a preclinical model of Alzheimer’s disease

Aug 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 115 references
Medicine

TL;DR

The data support the value of dMRIlow-b as a clinically feasible imaging tool for assessing alterations in CSF dynamics that mediate perivascular glymphatic clearance in the AD brain, accompanied by a reduced cognitive decline.

Abstract

Background Alzheimer’s disease (AD) is characterized by the excessive accumulation of select proteins in the brain, associated with altered vascular function, glymphatic transport, cerebrospinal fluid (CSF) dynamics, and cerebral microstructure. Exosomes derived from cerebral endothelial cells (CEC-Exo) have been demonstrated to reduce vascular dysfunction, which may beneficially impact perivascular glymphatic clearance, and potentially, protein aggregates and the corresponding microstructural disruption. Methods We investigated the effect of CEC-Exo therapy on AD by assessing glymphatic transport, CSF motion, and microstructural integrity using magnetic resonance imaging (MRI), and measuring cognitive performance. TgF344-AD rats, at 12-months of age, were randomly treated with CEC-Exo (1×1011 particles/intravenous injection) or saline twice-weekly for four consecutive weeks. MRI measurements, including dynamic 3D T1-weighted imaging with contrast agent and diffusion MRI (dMRI) with multiple b-values, were conducted for all rats at 13-months. Glymphatic function was evaluated with tracer-induced time signal curve (TSC), while microstructural state and CSF motion were assessed with parameters derived from dMRI acquired at high (dMRIhigh-b) and low (dMRIlow-b) b-values, respectively. Cognitive performance was assessed by the Morris water maze (MWM) test. Results TSCs demonstrated significantly higher peak values in the olfactory bulb and whole brain in the CEC-Exo-treated group than in the saline-treated group. With the CEC-Exo treatment, a significantly increased MDlow-b, a measure of pseudorandom CSF motion derived from dMRIlow-b, was observed in the representative CSF-filled space. As revealed by dMRIhigh-b-derived parameters, CEC-Exo treatment resulted in significantly elevated axonal water fraction, fractional anisotropy, and Kurtosis in white matter, as well as significantly reduced mean diffusivity, axial diffusivity, and radial diffusivity in both white and gray matter in the AD brain. In the MWM test, CEC-Exo-treated rats spent a significantly greater percentage of time in the correct quadrant than did saline-treated rats. Conclusion CEC-Exo treatment preserved glymphatic transport, CSF motion, and microstructural integrity in the AD brain, accompanied by a reduced cognitive decline. With a global therapeutic impact, the CEC-Exo therapy provides a novel strategy on the treatment of AD. Our data support the value of dMRIlow-b as a clinically feasible imaging tool for assessing alterations in CSF dynamics that mediate perivascular glymphatic clearance.

Read PDF

Similar papers

Open access Sep 2026

Human amniotic mesenchymal stromal cell-derived extracellular vesicles reprogram microglia and prevent neurodegeneration in experimental models of Alzheimer’s disease

HAMSC-EVs exert robust anti-inflammatory and neuroprotective effects in both murine and human AD models, improving cognition, modulating glial activation, and restoring synaptic integrity, and highlight the translational potential of intranasal hAMSC-EVs as an adjuvant therapeutic strategy targeting neuro inflammation...

Andrea Papait, F. Natale, A. Silini et al. · 0 citations
Open access Aug 2026

Therapeutic potential and underlying mechanisms of engineered young plasma-derived exosomes in Alzheimer's disease

The potential value of young plasma-derived EXOs in AD treatment is revealed for the first time and, through RVG engineering strategies and the elucidation of the RPTOR-autophagy mechanism, provides new insights for targeted therapy of neurodegenerative diseases.

Hang Chen, Yuanquan Si, Qian Cheng et al. · 0 citations
Aug 2026

Therapeutic Effects of miR-29b-Enriched Nanovesicles on Mitochondrial Injury and Neuroinflammatory Processes in Alzheimer’s Disease

Treatment with sEV-miR-29b attenuated Aβ-induced oxidative stress, reduced pro-inflammatory signaling, and improved mitochondrial homeostasis compared with Aβ-only and sEV-only groups, and sEV-miR-29b treatment partially restored synaptic protein expression and decreased pathological tau phosphorylation.

Sinan Gönüllü, E. Dalkılınç, Oğuz Çelik et al. · 0 citations
Open access Sep 2026

Engineering an Aβ-Induced 3D Alzheimer’s Disease Model via Magnetic Levitation for Neuroprotective Drug Screening

Background: This study aims to develop an amyloid-beta-induced three-dimensional (3D) Alzheimer’s disease model using the Magnetic Levitation (MagLev) technique and rat pheochromocytoma (PC-12) (rat pheochromocytoma) cells. Methods: Initially, optimization studies were performed to determine the appropriate paramagneti...

Rumeysa Bilginer-Kartal, A. Arslan-Yildiz · 0 citations
Review 2026

Nanoparticle-Based Therapeutics and Drug Delivery for Alzheimer’s Disease

The article aims to examine and discuss the performance and limitations of four NP formulations from different studies, finding polymer-based NPs modified with targeting peptides delivering rifampicin were found to be effective against Aβ accumulation in vivo.

Xi-Ran Wang · 0 citations
Sep 2026

Quantitative Assessment of Cerebrospinal Fluid-Vascular Association in Alzheimer's Disease Using Phase-Contrast and 4D-Flow Magnetic Resonance Imaging.

Altered CSF-vascular association was observed in Alzheimer's disease, suggesting possible glymphatic involvement, and the integration of CSF and vascular flow metrics provides a promising biomarker framework for early AD detection and monitoring.

Meng-Ying Lu, Yu-Shan Zheng, Ting-Ting Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.